Search Results
Nov 18, 2025, 08:30 ET Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
3-fold respectively, that of the Aramchol free acid 300mg tablets The new unexpected PK profile allows for a once daily therapeutic regimen thus potentially improving long term adherence and expected to significantly reduce the drug cost
More news about: Galmed Pharmaceuticals Ltd.
Nov 18, 2025, 08:00 ET Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals
and Sustained Clinical Cure. In the Phase 2 clinical trial (both trial segments), the Company also evaluated pharmacokinetics (PK) and microbiome changes and test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance,
More news about: Acurx Pharmaceuticals, Inc.
Nov 17, 2025, 09:07 ET Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation
small-molecule profile, exposure-guided strategy, and phase-appropriate GxP controls position it for a rigorous, stepwise program focused on safety, PK/PD, and functional endpoints. Our goal is to engage regulators early and, if data support, pursue rare-disease pathways that can responsibly accelerate
More news about: Atossa Therapeutics Inc
Nov 14, 2025, 05:08 ET EirGenix unterzeichnete die kommerzielle Lizenzvereinbarung für sein zweites HER2-Biosimilar EG1206A
EirGenix wird für die Produktentwicklung, Herstellung und Lieferung verantwortlich sein. EG1206A hat seine pharmakokinetische (PK) klinische Studie abgeschlossen und im vergangenen Monat sowohl von der US-amerikanischen FDA als auch von der Europäischen Arzneimittelagentur (EMA)
More news about: EirGenix, Inc.
Nov 13, 2025, 08:05 ET Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
development and commercial readiness. The FDA feedback and ongoing CMC planning follow the Company's earlier positive pharmacokinetic (PK) simulation analysis for TH104, which further reinforces its potential as a potentially superior prophylactic treatment for military personnel and chemical
More news about: Tharimmune, Inc.
Nov 13, 2025, 07:27 ET Natural Grocers® Serves Up Thanksgiving Hot Deals, Good Food and Gratitude
freshness and flavor. Waterloo® Sparking Waters ($5.29/12 pk) and San Pellegrino Sparking Mineral Water ($20.99/12 pk). Stretch your dollar and keep things sparkling with these non-alcoholic beverages.
More news about: Natural Grocers by Vitamin Cottage, Inc.
Nov 13, 2025, 07:00 ET Neurvati Neurosciences Appoints Carlos Martin as Chief Commercial Officer
(ClinicalTrials.gov identifier: NCT06392009) is an ongoing, open-label Phase 1b/2a clinical trial assessing the safety, tolerability, pharmacokinetics (PK), and potential efficacy of radiprodil in patients with TSC or FCD type II. About GRIN Therapeutics
More news about: Neurvati Neurosciences
Nov 12, 2025, 18:30 ET Ascletis Announces Co-formulation of ASC36, Once-Monthly Next-Generation Amylin Receptor Agonist and ASC35, Once-Monthly Next-Generation GLP-1R/GIPR Dual Agonist for Clinical Development
receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human primate studies. - ASC36
More news about: Ascletis Pharma Inc.
Nov 12, 2025, 08:45 ET EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
performance. EirGenix will be responsible for product development, manufacturing, and supply. EG1206A has completed its pharmacokinetic (PK) clinical study, and last month received positive feedback from both the U.S. FDA and the European Medicines Agency (EMA), confirming that the product
More news about: EirGenix, Inc.
Nov 12, 2025, 07:47 ET EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
performance. EirGenix will be responsible for product development, manufacturing, and supply. EG1206A has completed its pharmacokinetic (PK) clinical study, and last month received positive feedback from both the U.S. FDA and the European Medicines Agency (EMA), confirming that the product
More news about: EirGenix, Inc.
Nov 12, 2025, 03:00 ET AbolerIS Pharma Announces Publication in Molecular Therapy Cell Press Journal of New Preclinical Results Supporting Mechanism of Action of ABO21009, a First-in-Class Anti-CD45RC Antibody, Currently in Phase 1
study of ABO21009. Dr. Ronald van Brempt, MD, CMO of AbolerIS, mentions that a milestone has been reached. "Building on the highly encouraging safety and PK/PD results of the healthy volunteer part of the study, we can now start dosing the first patients suffering from Rheumatoid Arthritis (RA). Pending clinical
More news about: AbolerIS Pharma
Nov 12, 2025, 01:00 ET Imperial Hotel, Kyoto -- Opening March 5, 2026: Reservations to Open to Public on Monday, November 17, 2025, at 11:00 AM (JST)
https://cdn.kyodonewsprwire.jp/prwfile/release/M100588/202511048432/_prw_PI3fl_6k4PK4YF.jpg SuitesThese special rooms, located within the Main Building - Heritage
More news about: Imperial Hotel, Ltd.
Nov 11, 2025, 08:58 ET iLeukon Therapeutics Presents Phase I Data for ILKN421H at SITC 2025
favorable safety and tolerability relative to earlier-generation IL-2 therapeutics. Reliable and Robust PK/PDPharmacokinetic data from the Phase I study demonstrated prolonged IL-2v expression with a half-life of approximately 20 hours. Pharmacodynamic
More news about: iLeukon Therapeutics
Nov 11, 2025, 04:14 ET Comfee Hadirkan Kenyamanan Cerdas ke Rumah-Rumah Indonesia dengan Penawaran Menarik di Double 11!
20 pembeli teratas dari AC 1PK atau 1,5PK akan menerima bundle spesial Fino & Hair Oil. 50 pembeli teratas dari model 0,5PK akan mendapatkan TSUBAKI Shampoo. Gratis pemasangan untuk unit 0,5PK dan 1PK (hanya untuk layanan, terbatas
More news about: Comfee
Nov 10, 2025, 08:00 ET Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens
Clinical Cure. In the Phase 2 clinical trial (both trial segments), the Company also evaluated pharmacokinetics (PK) and microbiome changes and test for anti-recurrence microbiome properties, including the change from baseline in alpha diversity and bacterial abundance,
More news about: Acurx Pharmaceuticals, Inc.
Nov 10, 2025, 03:30 ET Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
ongoing AERIAL trial have established proof-of-concept for LEU011 by demonstrating key biological activity through evidence of encouraging pharmacokinetic (PK) and pharmacodynamic (PD) profiles. In particular, analysis of post-treatment biopsies (as evaluated by ddPCR and RNAScope) has shown tumour infiltration
More news about: Leucid Bio
Nov 09, 2025, 19:00 ET Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
placebo-controlled, single-ascending-dose trial in healthy subjects and patients with mild hypertension to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously administered IBI3016. As of July 1, 2025, 40 healthy subjects and mild hypertensive
More news about: Innovent Biologics
Nov 07, 2025, 08:00 ET PRM Pharma Announces Nationwide Availability of HemiClor® (Chlorthalidone) 12.5 mg: The First FDA-Approved Low-Dose Chlorthalidone Tablet Aligned With Hypertension Guidelines
high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288(23):2981-2997. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive
More news about: PRM Pharma, LLC
Nov 06, 2025, 19:10 ET ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut
molecule incorporates an engineered Fc region with reduced binding affinity for FcγR, which extends its in vivo half-life and optimizes its pharmacokinetic (PK) profile to support long-term dosing intervals. CS2015 also exhibits excellent molecular stability, facilitating the development of high-concentration
More news about: CStone Pharmaceuticals
Nov 06, 2025, 16:32 ET California Board of Education Approves Takeoff by IXL, California Edition
Currently used by 17 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a state-of-the-art assessment suite. Available in more than 100 languages, IXL's end-to-end
More news about: IXL Learning
Nov 06, 2025, 08:31 ET MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
reduction and decreases in waist circumference of up to 3.9 inches, with effects sustained for two weeks after dosing ended. Newly reported pharmacokinetic (PK) data showed linear, dose-proportional exposure and an approximately 80-hour half-life, supporting the feasibility of once-weekly dosing."
More news about: MetaVia Inc.
Nov 06, 2025, 08:00 ET Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025
the safety, tolerability, and efficacy of LPCN 2101, subject to resource prioritization. Pre-clinical and Phase 1 studies have demonstrated promising PK results, safety and tolerability. Two abstracts related to LPCN 2101 have been accepted for poster presentation at the 2025
More news about: Lipocine Inc.
Nov 05, 2025, 08:15 ET Introducing the Future of K-12 Assessment: The IXL LevelUp™ Diagnostic
Currently used by 17 million students and 96 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform providing a comprehensive PK-12 curriculum, instructional resources, actionable analytics and a state-of-the-art assessment suite. Available in more than 100 languages, IXL's end-to-end
More news about: IXL Learning
Nov 05, 2025, 07:00 ET HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
NCT06487624) is a multi-regional, multi-center, open-label, dose-finding, first-in-human trial evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical efficacy of HCB301 in patients with advanced solid tumors or relapsed and refractory classical Hodgkin
More news about: HanchorBio Inc.
Nov 04, 2025, 19:00 ET Multiple Research Results from Innovent's General Biomedicine Pipeline Showcased at 2025 ACR Annual Meeting
level of attention in recent years, and we have developed an innovative TACI/BCMA fusion protein (IBI3034) with excellent developability, function and PK profile. Among them, IBI3011 can be administered subcutaneously, and IBI3034 allows for long-interval dosing. Together, we hope that these differentiated
More news about: Innovent Biologics